Literature DB >> 2858926

Transsphenoidal surgery for acromegaly--long-term results in 100 patients.

F Grisoli, T Leclercq, P Jaquet, M Guibout, J P Winteler, J Hassoun, F Vincentelli.   

Abstract

A series of 100 patients with acromegaly who were operated on using the transsphenoidal microsurgical approach is presented along with a review of the literature. Emphasis is placed on long-term follow-up to assess the value of the technique. The authors caution against early normalization of growth hormone as a criterion for biologic cure in that cases of late recurrence are presented. It is proposed that 5 ng/mL baseline growth hormone values with normal dynamic testing is the most reliable way to ascertain biologic cure. Using these criteria, a cure rate of 78% for enclosed and 33% for invasive adenomata was obtained. No long-term recurrence was seen in patients considered cured along these lines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858926     DOI: 10.1016/0090-3019(85)90248-4

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  15 in total

Review 1.  Treatment options in acromegaly. Benefits and costs.

Authors:  L M Weekes; K K Ho; J P Seale
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

2.  Role of transsphenoidal operation in the management of pituitary adenomas with suprasellar extension.

Authors:  O Bynke; J Hillman
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 3.  The management of the patient with acromegaly and headache: a still open clinical challenge.

Authors:  A Giustina; M Gola; A Colao; L De Marinis; M Losa; N Sicolo; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

4.  Factors predicting pituitary adenoma invasiveness in acromegalic patients.

Authors:  A Rieger; N G Rainov; H Ebel; L Sanchin; K Shibib; C Helfrich; O Hoffmann; W Burkert
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

5.  Serum IGF-I and IGFBP-3 levels for the assessment of disease activity of acromegaly.

Authors:  H S Chen; H D Lin
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

6.  Gingival enlargement in acromegaly.

Authors:  I Capoglu; A B Yilmaz; N Unüvar; R Orbak; H Aksoy; H Yesilyurt
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

Review 7.  Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results.

Authors:  Pedro Carvalho; Eva Lau; Davide Carvalho
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

8.  Herniation of cerebellar tonsils in acromegaly: prevalence, pathogenesis and clinical impact.

Authors:  Renzo Manara; Giulia Bommarito; Silvia Rizzati; Chiara Briani; Alessandro Della Puppa; Valentina Citton; Eva Zanchetta; Fabio Zerbo; Mario Ermani; Chiara Martini; Franco Mantero; Nicola Sicolo; Pietro Maffei; Carla Scaroni
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

Review 9.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

10.  Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.

Authors:  G Mehltretter; S Heinz; J Schopohl; K von Werder; O A Müller
Journal:  Klin Wochenschr       Date:  1991-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.